TABLE OF CONTENTS 1 2 INTRODUCTION ...... 1 3 PARTIES ...... 6 4 Plaintiff ...... 6
5 Defendants ...... 7
6 Avastin ...... 7 7 Rituxan ...... 8 Kadcyla ...... 8 8 Xolair ...... 9 9 JURISDICTION AND VENUE ...... 10 10 FACTUAL ALLEGATIONS REGARDING GENENTECH’S LIABILITY ...... 10 11 12 The Bach Article ...... 10 13 Other Investigators Agree with Bach ...... 12 14 Amounts that Class Members Needlessly Spend on Unusable Mediations Are Substantial ...... 14 15 Avastin ...... 14 16 Rituxan ...... 15 17 Kadcyla ...... 16 18 Xolair ...... 16
19 How Genentech Could Have Easily Reduced the Amount of Waste ...... 18
20 Two Manufacturers That Minimize Waste ...... 20 21 Treanda ...... 20 22 Lartruvo...... 21
23 Genentech Offered a Smaller Size of Xolair in Europe, but Not in the United States ...... 23 24 25 FACTS RELATED TO PLAINTIFF’S TREATMENT WITH GENENTECH’S DRUGS ...... 23 26 GENENTECH’S SCHEME ORIGINATED AND IS DIRECTED FROM CALIFORNIA ...... 25
27 CLASS ACTION ALLEGATIONS ...... 29
28 FIRST CLAIM FOR RELIEF ...... 31